

**Notice Regarding Adjustment of 340B Prices for Select Products of Esperion Therapeutics, Inc.**

**Esperion Therapeutics, Inc.** has recalculated its 340B ceiling prices for the period from **2Q2020 through 3Q2020** for the products listed below due to revisions made to their Medicaid pricing data. **Esperion Therapeutics, Inc.** has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about **Esperion Therapeutics, Inc's** recalculation affecting certain 340B Covered Entities for the impacted product(s).

**Esperion Therapeutics, Inc.** has determined the credit amount owed to each affected covered entity. **Esperion Therapeutics, Inc.** will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity's validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified.

NDC	Product Description
72426-0118-03	NEXLETOL
72426-0818-03	NEXLIZET

If a Covered Entity believes they are due a refund and are not contacted by Apexus by May 1, 2021, you may contact Tom Tobin, **Esperion Therapeutics, Inc.**, Sr. Director, Contracting & Trade, at [ttobin@esperion.com](mailto:ttobin@esperion.com).